FDA records on compounded GLP-1 sellers

Every FDA warning letter and recall report naming compounded or unapproved semaglutide, tirzepatide and related drugs, company by company, with links to the originals.

Records updated Nov 15, 2026

155

FDA warning letters

Letters whose text names semaglutide, tirzepatide, retatrutide, liraglutide or cagrilintide sold outside FDA approval. FDA issued 75 of them in 2026.

108

Telehealth companies warned

Companies FDA describes as telehealth companies in the subject line of a GLP-1 warning letter, across 111 letters.

81

Recall reports

openFDA recall reports for compounded or unapproved GLP-1 products from 17 firms. The most common reason FDA recorded is “Lack of assurance of sterility.”

15

Letters citing research-use labeling

Warning letters that quote “research use,” “for research purposes” or “not for human consumption” labeling on GLP-1 products.

Latest FDA warning letters

Later letters FDA listsLetter
Oct 30, 2026RonanRx, Inc. dba RonanRxFalse & Misleading Claims/Misbranded (Telehealth)Semaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov
Sep 24, 2026Cheap Medicine Shop/www.cheapmedicineshop.comUnapproved New Drugs/Misbranded (Internet Pharmacy)SemaglutideNone listed by FDA as of Nov 15, 2026fda.gov
Sep 23, 2026Online Generic Medicine/www.onlinegenericmedicine.comUnapproved New Drug/Misbranded (Internet Pharmacy)SemaglutideNone listed by FDA as of Nov 15, 2026fda.gov
Sep 18, 2026Empower Clinic Services, LLC dba Empower PharmacyCGMP/Finished Pharmaceuticals/Adulterated/Unapproved New DrugSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov
Aug 24, 2026TXP Innovations LLC dba Tex PeptidesUnapproved New Drugs/MisbrandedSemaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Aug 24, 2026Royal Peptides LLCUnapproved New Drugs/MisbrandedSemaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Aug 24, 2026NuScience Peptides LLCUnapproved New Drugs/MisbrandedSemaglutide, Retatrutide, Survodutide, MazdutideNone listed by FDA as of Nov 15, 2026fda.gov
Aug 24, 2026Peptide Partners LLCUnapproved New Drugs/MisbrandedSemaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Aug 24, 2026Peak Performance PeptidesUnapproved New Drugs/MisbrandedSemaglutide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Jun 8, 2026Maximus Health, Inc. dba MaximusFalse & Misleading Claims/Misbranded (Telehealth)Semaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

All 155 warning letters

Browse

Questions answered from the records

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.